Providing insurance coverage for multicancer early detection (MCED) tests is vital to reduce disparities in access, said Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco.
Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco, talks about the ways multicancer early detection (MCED) tests can reduce disparities.
Transcript
How can MCED tests both reduce or widen disparities in cancer screening, and what are some possible solutions?
I think there are some theoretical ways that these tests could reduce disparities. I say that because, currently, we don't have clear evidence that these tests have net benefits; we haven't demonstrated clinical utility yet. With that sort of caveat, I do think that, potentially, the ease of use of a single blood draw could potentially reduce disparities if there were barriers to access to screening tests for certain disadvantaged populations, whether that be geography or socioeconomic status or cultural beliefs, so that may help to reduce disparities.
I also think if they can detect more aggressive cancers, we know that those disproportionately affect minority patients, so that could potentially be a way to reduce disparities. Frankly, most people can't pay $1000 out-of-pocket for 1 of these tests. The biggest way to reduce disparities, again assuming that these tests have clinical utility, is to provide insurance coverage. Many screening tests, for example those with the USPSTF rating of A or B, have first dollar coverage, meaning there's no out-of-pocket expense for access to the screening test. I think all of those would be important because, currently, the only people right now that have access to the test are people that can pay out-of-pocket. It may also be that some physicians that treat the majority of their patient population are disadvantaged patients. They may need additional educational support to make sure that there's appropriate use of these tests.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More